← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Oleolive, Inc.
Shreveport, LA
$4,698,792
Total funding
6
Grants
Funding over time
peak $2.1M · FY2018–25$2.5M$1.9M$1.3M$625K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,698,792 · 6
By mechanism
R42$2,747,975 · 1
R41$1,164,171 · 3
R43$786,646 · 2
Investigators at Oleolive, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
Evaluation of a dual PPAR agonist for treatment of Alzheimer's disease$1,692,440
R42 · FY2022 · AG
Evaluation of a dual PPAR agonist for treatment of Alzheimer's disease$805,761
R42 · FY2023 · AG
Oleocanthal functional food products for breast cancer recurrence control$399,999
R41 · FY2020 · CA
Chemosensitization of Glioblastoma by Propentofylline$399,998
R41 · FY2022 · CA
Evaluation of a selective PPAR-gamma agonist for treatment of Alzheimerâs Disease$346,991
R43 · FY2019 · AG
Repurposing Pyrvinium as an Inhalation Therapy for Idiopathic Pulmonary Fibrosis$309,418
R41 · FY2025 · HL
Evaluation of oral oleocanthal to prevent and/or treat Alzheimerâs disease and related dementias$269,634
R43 · FY2018 · AG
Evaluation of a dual PPAR agonist for treatment of Alzheimer's disease$249,774
R42 · FY2023 · AG
Evaluation of a selective PPAR-gamma agonist for treatment of Alzheimerâs Disease$103,008
R43 · FY2020 · AG
Evaluation of oral oleocanthal to prevent and/or treat Alzheimerâs disease and related dementias$67,013
R43 · FY2019 · AG
Oleocanthal functional food products for breast cancer recurrence control$54,756
R41 · FY2021 · CA